Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation

[1]  R. Schwarzer,et al.  Coping and quality of life after tumor surgery: Personal and social resources promote different domains of quality of life , 2007, Anxiety, stress, and coping.

[2]  Jinlin Yang,et al.  [The effect of genistein on the proliferation of human hepatocellular carcinoma cell SMMC-7721]. , 2006, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[3]  N. Ferakis,et al.  Quality of life after laparoscopic and open retroperitoneal lymph node dissection in clinical Stage I nonseminomatous germ cell tumor: a comparison study. , 2006, Urology.

[4]  Z. Yao,et al.  The effect of tripeptide tyroserleutide (YSL) on animal models of hepatocarcinoma , 2006, Peptides.

[5]  E. Shaw,et al.  Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Shacter,et al.  Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin. , 2005, Free radical biology & medicine.

[7]  Sun Yan-li.  PTEN inhibits cell growth and increases chemosensitivity to doxorubicin of human breast cancer cells , 2005 .

[8]  Z. Yao,et al.  Experimental study of the inhibition of human hepatocarcinoma Bel7402 cells by the tripeptide tyroserleutide(YSL) , 2005, Cancer Chemotherapy and Pharmacology.

[9]  J. Foekens,et al.  Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer. , 2004, International journal of oncology.

[10]  M. Volm,et al.  Sensitivity tests of tumors to cytostatic agents , 2004, Zeitschrift für Krebsforschung und Klinische Onkologie.

[11]  M. Volm,et al.  Sensitivity tests of tumors to cytostatic agents , 2004, Zeitschrift für Krebsforschung und Klinische Onkologie.

[12]  S. Kaye,et al.  Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy , 2004, Cancer Chemotherapy and Pharmacology.

[13]  Li-hong Xu,et al.  Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480. , 2003, World journal of gastroenterology.

[14]  G. Anselmi,et al.  Differential long-term subcellular responses in heart and liver to adriamycin stress. Exogenous L-carnitine cardiac and hepatic protection. , 2002, Journal of submicroscopic cytology and pathology.

[15]  M. Bernstein,et al.  Quality of life in patients with brain tumor: what's relevant in our quest for therapeutic efficacy. , 1998, Neurosurgical focus.

[16]  G. Ghiggeri,et al.  Lysyl oxidase expression and collagen cross-linking during chronic adriamycin nephropathy. , 1997, Nephron.

[17]  M. Igawa,et al.  Association between patient characteristics and treatment history, and toxicity associated with methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) for advanced urothelial cancer. , 1994, British journal of urology.

[18]  R. Mueller,et al.  Doxorubicin toxicity in perfused rat heart. Decreased cell death at low oxygen tension. , 1991, Circulation research.

[19]  P. Singal,et al.  Subcellular effects of adriamycin in the heart: a concise review. , 1987, Journal of molecular and cellular cardiology.

[20]  F. Uckun,et al.  Combined immunochemotherapy of human solid tumors in nude mice. , 1987, Cancer research.

[21]  J. Pitha,et al.  A clinicopathologic analysis of adriamycin cardiotoxicity , 1973, Cancer.